GlassScriptPhysician profile
Daniel A Sanchez Taboada
NPI 1922565027
$3,384.65
in general payments reported to CMS, 2019-2025
30 companies · $988 in 2025
The $988 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2021: $31.54 · 2022: $133 · 2023: $450 · 2024: $1,670 · 2025: $988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,380 · Education: $727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,380.48 |
| Education | $727.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $403.19 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Pfizer INC. | $389.85 | 2022-2025 | |
| Sobi, INC | $304.43 | 2024-2025 | |
| Celgene Corporation | $285.52 | 2024-2025 | Reblozyl |
| Astrazeneca Pharmaceuticals LP | $282.90 | 2024-2025 | Tagrisso, Calquence, Enhertu |
| Janssen Biotech, INC. | $204.40 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Merck Sharp & Dohme LLC | $185.66 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $167.65 | 2023-2024 | |
| Astellas Pharma US INC | $148.08 | 2023-2025 | Xtandi |
| Genentech USA, INC. | $112.56 | 2019 | |
| Eisai INC. | $99.86 | 2023-2024 | |
| Seagen INC. | $91.26 | 2022-2023 | Tukysa |
| Exelixis INC. | $89.99 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $77.47 | 2023-2024 | Iclusig, Ninlaro |
| Genzyme Corporation | $76.94 | 2023-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $48.46 | 2024 | Clonoseq |
| Glaxosmithkline, LLC. | $46.98 | 2023-2025 | Zejula, Jemperli |
| Janssen Pharmaceuticals, INC | $45.37 | 2021-2023 | Xarelto |
| Abbvie INC. | $45.21 | 2025 | |
| Tolmar, INC. | $42.02 | 2023-2024 | |
| Tempus Ai, INC | $37.32 | 2024 | Xt Cdx |
| Pharmacosmos Therapeutics INC. | $31.42 | 2023-2024 | Monoferric |
| Deciphera Pharmaceuticals INC. | $30.08 | 2024 | Qinlock |
| Mirati Therapeutics, INC. | $23.54 | 2023 | Krazati |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.92 | 2024 | Gilotrif |
| Emd Serono, INC. | $22.21 | 2025 | |
| Taiho Oncology, INC. | $20.41 | 2024 | |
| Stemline Therapeutics INC. | $17.91 | 2025 | Orserdu |
| Aurinia Pharma U.S., INC. | $16.05 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.99 | 2024 | Truxima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sanchez Taboada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.